Angiogenesis in non-Hodgkin's lymphoma: Clinico-pathological correlations and prognostic significance in specific subtypes

Leukemia and Lymphoma

Volumn 48, Issue 3, 2007, Pages 584-595

  Jorgensen J M ^a   Sorensen F B ^a   Bendix, K ^a   Nielsen, J L ^a   Olsen, M L ^b   Funder, A M D ^a   D'amore, Francisco ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Angiogenesis; Chalkley method; Microvessel density method (MVD); Non Hodgkin's lymphoma (NHL); Prognosis

Indexed keywords

ANGIOGENIC FACTOR; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VASCULOTROPIN; VINCRISTINE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MARROW BIOPSY; CANCER STAGING; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR BIOPSY; TUMOR VASCULARIZATION; WHOLE BODY TOMOGRAPHY;

AGED; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33947678733     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601083241     Document Type: Article

References (64)

1. Folkman, J. (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med, 285, pp. 1182-1186.
2. Folkman, J. and Klagsbrun, M. (1987) Angiogenic factors. Science, 235, pp. 442-447.
3. Ellegaard, J. and Nielsen, J. L. (1999) Angiogenesis in malignant blood diseases. Ugeskr Laeger, 161, p. 4012.
4. Mangi, M. H. and Newland, A. C. (2000) Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol, 111, pp. 43-51.
5. Veikkola, T. and Alitalo, K. (1999) VEGFs, receptors and angiogenesis. Semin Cancer Biol, 9, pp. 211-220.
6. Neufeld, G., Tessler, S., Gitay-Goren, H., Cohen, T. and Levi, B. Z. (1994) Vascular endothelial growth factor and its receptors. Prog Growth Factor Res, 5, pp. 89-97.
7. Olofsson, B., Pajusola, K., Kaipainen, A., von, E. G., Joukov, V. and Saksela, O. (1996) Vascular endothelial growth actor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci, 93, pp. 2576-2581.
8. Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I. K. and Alitalo (1996) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J, 15, pp. 290-298.
9. Achen, M. G., Jeltsch, M., Kukk, E., Makinen, T., Vitali, A. and Wilks, A. F. (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci, 95, pp. 548-553.
10. Hansen, S., Grabau, D. A., Rose, C., Bak, M. and Sorensen, F. B. (1998) Angiogenesis in breast cancer: A comparative study of the observer variability of methods for determining microvessel density. Lab Invest, 78, pp. 1563-1573.
11. Fox, S. B., Leek, R. D., Weekes, M. P., Whitehouse, R. M., Gatter, K. C. and Harris, A. L. (1995) Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol, 177, pp. 275-283.
12. Hlatky, L., Hahnfeldt, P. and Folkman, J. (2002) Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst, 94, pp. 883-893.
13. Vermeulen, P. B., Gasparini, G., Fox, S. B., Toi, M., Martin, L. and McCulloch, P. (1996) Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation. Eur J Cancer, 32, pp. 2474-2484.
14. Macchiarini, P., Fontanini, G., Hardin, M. J., Squartini, F. and Angeletti, C. A. (1992) Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet, 340, pp. 145-146.
15. Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W. and Folkman, J. (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol, 143, pp. 401-409.
16. Maeda, K., Chung, Y. S., Takatsuka, S., Ogawa, Y., Onoda, N. and Sawada, T. (1995) Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer, 72, pp. 319-323.
17. Toi, M., Inada, K., Suzuki, H. and Tominaga, T. (1995) Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat, 36, pp. 193-204.
18. Hansen, S., Sorensen, F. B., Vach, W., Grabau, D. A., Bak, M. and Rose, C. (2004) Microvessel density compared with the Chalkley count in a prognostic study of angiogenesis in breast cancer patients. Histopathology, 44, pp. 428-436.
19. Hansen, S., Grabau, D. A., Sorensen, F. B., Bak, M., Vach, W. and Rose, C. (2000) The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res, 6, pp. 139-146.
20. Hansen, S., Grabau, D. A., Sorensen, F. B., Bak, M., Vach, W. and Rose, C. (2000) Vascular grading of angiogenesis: Prognostic significance in breast cancer. Br J Cancer, 82, pp. 339-347.
21. Hussong, J. W., Rodgers, G. M. and Shami, P. J. (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood, 95, pp. 309-313.
22. Aguayo, A., Kantarjian, H., Manshouri, T., Gidel, C., Estey, E. and Thomas, D. (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 96, pp. 2240-2245.
23. Ribatti, D., Vacca, A., Nico, B., Quondamatteo, F., Ria, R. and Minischetti, M. (1999) Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer, 79, pp. 451-455.
24. Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F. and Dammacco, F. (1994) Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol, 87, pp. 503-508.
25. Pruneri, G., Ponzoni, M., Ferreri, A. J., Decarli, N., Tresoldi, M. and Raggi, F. (2002) Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol, 118, pp. 817-820.
26. Andersen, N. F., Standal, T., Nielsen, J. L., Heickendorff, L., Borset, M., Sorensen, F. B. and Abildgaard, N. (2005) Syndecan-1 and angiogenic cytokines in multiple myeloma: Correlation with bone marrow angiogenesis and survival. Br J Haematol, 128, pp. 210-217.
27. Vacca, A., Ribatti, D., Roncali, L. and Dammacco, F. (1995) Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk Lymphoma, 20, pp. 27-38.
28. Vacca, A., Ribatti, D., Fanelli, M., Costantino, F., Nico, B. and Di, S. R. (1996) Expression of tenascin is related to histologic malignancy and angiogenesis in b-cell non-Hodgkin's lymphomas. Leuk Lymphoma, 22, pp. 473-481.
29. Ribatti, D., Vacca, A., Nico, B., Fanelli, M., Roncali, L. and Dammacco, F. (1996) Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol, 56, pp. 45-53.
30. Vacca, A., Ribatti, D., Ruco, L., Giacchetta, F., Nico, B. and Quondamatteo, F. (1999) Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer, 79, pp. 965-970.
31. Ribatti, D., Vacca, A., Marzullo, A., Nico, B., Ria, R., Roncali, L. and Dammacco, F. (2000) Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Int J Cancer, 85, pp. 171-175.
32. Crivellato, E., Nico, B., Vacca, A. and Ribatti, D. (2003) B-cell non-Hodgkin's lymphomas express heterogeneous patterns of neovascularization. Haematologica, 88, pp. 671-678.
33. Arias, V. and Soares, F. A. (2000) Vascular density (tumor angiogenesis) in non-Hodgkin's lymphomas and florid follicular hyperplasia: A morphometric study. Leuk Lymphoma, 40, pp. 157-166.
34. Fukushima, N., Satoh, T., Sano, M. and Tokunaga, O. (2001) Angiogenesis and mast cells in non-Hodgkin's lymphoma: A strong correlation in angioimmunoblastic T-cell lymphoma. Leuk Lymphoma, 42, pp. 709-720.
35. Hazar, B., Paydas, S., Zorludemir, S., Sahin, B. and Tuncer, I. (2003) Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma, 44, pp. 2089-2093.
36. Bairey, O., Zimra, Y., Kaganovsky, E., Shaklai, M., Okon, E. and Rabizadeh, E. (2000) Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Med Oncol, 17, pp. 314-318.
37. Koster, A., van Krieken, J. H., Mackenzie, M. A., Schraders, M., Borm, G. F. and van der Laak, J. A. (2005) Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res, 11, pp. 154-161.
38. Salven, P., Teerenhovi, L. and Joensuu, H. (1999) A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood, 94, pp. 3334-3339.
39. Salven, P., Orpana, A., Teerenhovi, L. and Joensuu, H. (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients. Blood, 96, pp. 3712-3718.
40. Giles, F. J., Vose, J. M., Do, K. A., Johnson, M. M., Manshouri, T. and Bociek, G. (2004) Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res, 28, pp. 595-604.
41. Niitsu, N., Okamato, M., Nakamine, H., Yoshino, T., Tamaru, J. and Nakamura, S. (2002) Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol, 68, pp. 91-100.
42. Bertolini, F., Paolucci, M., Peccatori, F., Cinieri, S., Agazzi, A. and Ferrucci, P. F. (1999) Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol, 106, pp. 504-509.
43. Salven, P., Teerenhovi, L. and Joensuu, H. (1997) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood, 90, pp. 3167-3172.
44. Bono, P., Teerenhovi, L. and Joensuu, H. (2003) Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer, 97, pp. 2767-2775.
45. Aref, S., Mabed, M., Zalata, K., Sakrana, M. and El, A. H. (2004) The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): Relationship to patient outcome. Leuk Lymphoma, 45, pp. 499-506.
46. Ho, C. L., Sheu, L. F. and Li, C. Y. (2002) Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. Appl Immunohistochem Mol Morphol, 10, pp. 316-321.
47. Ho, C. L., Sheu, L. F. and Li, C. Y. (2003) Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma. Ann Diagn Pathol, 7, pp. 1-8.
48. Jaffe, E. S., Harris, N. L., Stein, H. and Vardiman, J. W. (2001) WHO Classification of Tumours, Pathology and Genetics of Tumours of Haemopoetic and Lymphoid Tissues, IARC Press, Lyon
49. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, pp. 1244-1253.
50. Yuen, A. R., Kamel, O. W., Halpern, J. and Horning, S. J. (1995) Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol, 13, pp. 1726-1733.
51. Bastion, Y., Sebban, C., Berger, F., Felman, P., Salles, G. and Dumontet, C. (1997) Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol, 15, pp. 1587-1594.
52. Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D. and Chan, W. C. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med, 351, pp. 2159-2169.
53. Ribatti, D., Nico, B., Vacca, A., Marzullo, A., Calvi, N. and Roncali, L. (1998) Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas?. Br J Cancer, 77, pp. 1900-1906.
54. Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J. O. and Arranz-Saez, R. (2004) Follicular lymphoma international prognostic index. Blood, 104, pp. 1258-1265.
55. Went, P., Agostinelli, C., Gallamini, A., Piccaluga, P. P., Ascani, S. and Sabattini, E. (2006) Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score. J Clin Oncol, 24, pp. 2472-2479.
56. Perea, G., Altes, A., Montoto, S., Lopez-Guillermo, A., Domingo-Domenech, E. and Fernandez-Sevilla, A. (2005) Prognostic indexes in follicular lymphoma: A comparison of different prognostic systems. Ann Oncol, 16, pp. 1508-1513.
57. Ansell, S. M., Habermann, T. M., Kurtin, P. J., Witzig, T. E., Chen, M. G. and Li, C. Y. (1997) Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol, 15, pp. 2296-2301.
58. Sonnen, R., Schmidt, W. P., Muller-Hermelink, H. K. and Schmitz, N. (2005) The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol, 129, pp. 366-372.
59. De, R. H., Van, M. E., Van, C. B. and Vanderkerken, K. (2004) Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies. Histol Histopathol, 19, pp. 935-950.
60. Potti, A., Ganti, A. K., Kargas, S. and Koch, M. (2002) Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res, 22, pp. 2899-2901.
61. Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J. and Holash, J. (2000) Vascular-specific growth factors and blood vessel formation. Nature, 407, pp. 242-248.
62. Jiang, W. G., Martin, T. A., Parr, C., Davies, G., Matsumoto, K. and Nakamura, T. (2005) Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol, 53, pp. 35-69.
63. Jussila, L. and Alitalo, K. (2002) Vascular growth factors and lymphangiogenesis. Physiol Rev, 82, pp. 673-700.
64. Seidel, C., Borset, M., Hjertner, O., Cao, D., Abildgaard, N. and Hjorth-Hansen, H. (2000) High levels of soluble syndecan-1 in myeloma-derived bone marrow: Modulation of hepatocyte growth factor activity. Blood, 96, pp. 3139-3146.